Jane Street Group LLC Purchases 35,546 Shares of HilleVax, Inc. (NASDAQ:HLVX)

Jane Street Group LLC boosted its position in HilleVax, Inc. (NASDAQ:HLVX) by 81.7% in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 79,039 shares of the company’s stock after purchasing an additional 35,546 shares during the period. Jane Street Group LLC owned approximately 0.16% of HilleVax worth $139,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors have also added to or reduced their stakes in HLVX. BML Capital Management LLC bought a new stake in HilleVax in the third quarter worth about $35,000. GSA Capital Partners LLP bought a new stake in HilleVax in the third quarter worth about $126,000. Maven Securities LTD bought a new stake in HilleVax in the second quarter worth about $217,000. Verition Fund Management LLC bought a new stake in HilleVax in the third quarter worth about $331,000. Finally, Algert Global LLC bought a new stake in HilleVax in the second quarter worth about $519,000. Institutional investors own 86.42% of the company’s stock.

HilleVax Stock Performance

Shares of NASDAQ:HLVX opened at $2.00 on Tuesday. The firm has a market cap of $99.61 million, a PE ratio of -0.65 and a beta of 0.75. The firm’s 50 day simple moving average is $1.94 and its 200-day simple moving average is $2.37. HilleVax, Inc. has a one year low of $1.55 and a one year high of $20.22.

HilleVax (NASDAQ:HLVX) last issued its earnings results on Thursday, November 7th. The company reported ($0.52) EPS for the quarter, missing analysts’ consensus estimates of ($0.42) by ($0.10). Equities research analysts predict that HilleVax, Inc. will post -2.64 EPS for the current fiscal year.

HilleVax Company Profile

HilleVax, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel vaccines in the United States. It develops HIL-214, a virus-like particle-based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis caused by norovirus infection. The company was formerly known as MokshaCo, Inc and changed its name to HilleVax, Inc in February 2021.